Brain uptake and receptor binding of two [11C]labelled selective high affinity NK1-antagonists, GR203040 and GR205171 -: PET studies in rhesus monkey

被引:55
作者
Bergström, M [1 ]
Fasth, KJ
Kilpatrick, G
Ward, P
Cable, KM
Wipperman, MD
Sutherland, DR
Langström, B
机构
[1] Univ Uppsala Hosp, PET Ctr, S-75185 Uppsala, Sweden
[2] Glaxo Wellcome Res & Dev Ltd, Stevenage SG1 2NY, Herts, England
关键词
NK1; PET; primates; brain; pharmacokinetics;
D O I
10.1016/S0028-3908(99)00182-3
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Two high affinity and selective NK1-receptor antagonists, GR203040 and GR205171, were labelled with C-11 and used in a series of experiments in rhesus monkeys. The purpose of these studies was to evaluate the brain uptake pattern and to explore the potential use of these compounds as PET ligands to characterise NK1-receptor binding. Seventeen studies were carried out with [C-11]GR205171 and five experiments with [C-11]GR203040, including baseline studies and studies performed after a 5 min infusion of cold compound at doses between 0.05 and 1 mg/kg. Both compounds demonstrated a significant and rapid uptake in the brain, but the uptake of [C-11]GR205171 was more than double the uptake of [C-11]GR203040. At tracer doses of [C-11]GR205171 and all doses of [C-11]GR203040 the uptake reached a plateau with no washout during the examination time, whereas [C-11]GR205171 after pre-treatment with cold GR205171 showed a significant washout. Using a model with the cerebellum as reference, a method for quantitation was applied to the studies with [C-11]GR205171 and the results indicated that the highest specific binding was in the striatum. The pre-treatment dose of cold GR205171 needed for 50% inhibition of binding was less than 0.04 mg/kg. The studies indicated that [C-11]GR205171 could be used for the in vivo characterisation of NK1-receptor binding. (C) 2000 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:664 / 670
页数:7
相关论文
共 14 条
[1]   The pharmacology of GR203040, a novel, potent and selective non-peptide tachykinin NK1 receptor antagonist [J].
Beattie, DT ;
Beresford, IJM ;
Connor, HE ;
Marshall, FH ;
Hawcock, AB ;
Hagan, RM ;
Bowers, J ;
Birch, PJ ;
Ward, P .
BRITISH JOURNAL OF PHARMACOLOGY, 1995, 116 (08) :3149-3157
[2]   MEASUREMENT OF HUMAN CEREBRAL MONOAMINE-OXIDASE TYPE-B (MAO-B) ACTIVITY WITH POSITRON EMISSION TOMOGRAPHY (PET) - A DOSE RANGING STUDY WITH THE REVERSIBLE INHIBITOR RO-19-6327 [J].
BENCH, CJ ;
PRICE, GW ;
LAMMERTSMA, AA ;
CREMER, JC ;
LUTHRA, SK ;
TURTON, D ;
DOLAN, RJ ;
KETTLER, R ;
DINGEMANSE, J ;
DAPRADA, M ;
BIZIERE, K ;
MCCLELLAND, GR ;
JAMIESON, VL ;
WOOD, ND ;
FRACKOWIAK, RSJ .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1991, 40 (02) :169-173
[3]   MAO-A inhibition in brain after dosing with esuprone, moclobemide and placebo in healthy volunteers: In vivo studies with positron emission tomography [J].
Bergstrom, M ;
Westerberg, G ;
Nemeth, G ;
Traut, M ;
Gross, G ;
Greger, G ;
MullerPeltzer, H ;
Safer, A ;
Eckernas, SA ;
Grahner, A ;
Langstrom, B .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1997, 52 (02) :121-128
[4]  
Breeman WAP, 1996, J NUCL MED, V37, P108
[5]   SYNTHESIS OF A NONPEPTIDE C-11 LABELED SUBSTANCE-P ANTAGONIST FOR PET STUDIES [J].
DELROSARIO, RB ;
MANGNER, TJ ;
GILDERSLEEVE, DL ;
SHREVE, PD ;
WIELAND, DM ;
LOWE, JA ;
DROZDA, SE ;
SNIDER, RM .
NUCLEAR MEDICINE AND BIOLOGY, 1993, 20 (04) :545-547
[6]   PHYLOGENY OF TACHYKININ RECEPTOR LOCALIZATION IN THE VERTEBRATE CENTRAL-NERVOUS-SYSTEM - APPARENT ABSENCE OF NEUROKININ-2 AND NEUROKININ-3 BINDING-SITES IN THE HUMAN BRAIN [J].
DIETL, MM ;
PALACIOS, JM .
BRAIN RESEARCH, 1991, 539 (02) :211-222
[7]   MONOAMINE OXIDASE-B (MAO-B) INHIBITOR THERAPY IN PARKINSONS-DISEASE - THE DEGREE AND REVERSIBILITY OF HUMAN BRAIN MAO-B INHIBITION BY RO 19 6327 [J].
FOWLER, JS ;
VOLKOW, ND ;
LOGAN, J ;
SCHLYER, DJ ;
MACGREGOR, RR ;
WANG, GJ ;
WOLF, AP ;
PAPPAS, N ;
ALEXOFF, D ;
SHEA, C ;
GATLEY, SJ ;
DORFLINGER, E ;
YOO, K ;
MORAWSKY, L ;
FAZZINI, E .
NEUROLOGY, 1993, 43 (10) :1984-1992
[8]   The broad-spectrum anti-emetic activity of the novel non-peptide tachykinin NK1 receptor antagonist GR203040 [J].
Gardner, CJ ;
Twissell, DJ ;
Dale, TJ ;
Gale, JD ;
Jordan, CC ;
Kilpatrick, GJ ;
Bountra, C ;
Ward, P .
BRITISH JOURNAL OF PHARMACOLOGY, 1995, 116 (08) :3158-3163
[9]   GR205171: A novel antagonist with high affinity for the tachykinin NK1 receptor, and potent broad-spectrum anti-emetic activity [J].
Gardner, CJ ;
Armour, DR ;
Beattie, DT ;
Gale, JD ;
Hawcock, AB ;
Kilpatrick, GJ ;
Twissell, DJ ;
Ward, P .
REGULATORY PEPTIDES, 1996, 65 (01) :45-53
[10]   PERFORMANCE-CHARACTERISTICS OF AN 8-RING WHOLE-BODY PET SCANNER [J].
KOPS, ER ;
HERZOG, H ;
SCHMID, A ;
HOLTE, S ;
FEINENDEGEN, LE .
JOURNAL OF COMPUTER ASSISTED TOMOGRAPHY, 1990, 14 (03) :437-445